CLINICAL ROLE -
Treatment for Relapsed/Refractory Multiple Myeloma Shows Promising Clinical Activity, Safety
Teclistamab showed promising clinical activity and a tolerable safety profile in patients with relapsed/refractory multiple myeloma.
Zanidatamab Gets FDA Breakthrough Designation for HER2 Gene–Amplified Biliary Tract Cancer
The FDA has granted a breakthrough therapy designation to zanidatamab for the treatment of patients with HER2 gene–amplified biliary tract cancer who have received prior therapy.
FDA Approves FoundationOne CDx Genomic Test as Companion Diagnostic for Larotrectinib
The FDA has approved the FoundationOne CDx (F1CDx) comprehensive genomic test as a companion diagnostic for larotrectinib (Vitrakvi) to identify patients with NTRK1/2/3 gene fusions across all solid tumors.
FDA Fast Tracks Combination Therapy for Chronic Lymphocytic Leukemia
The FDA granted fast track designation to the investigational CD20-directed monoclonal antibody ublituximab in combination with the PI3K-delta inhibitor umbralisib for the treatment of chronic lymphocytic leukemia.
2 Clarke Drive Cranbury, NJ 08512